Nantahala Capital Management’s Abeona Therapeutics ABEO Stock Holding History

Nantahala Capital Management’s Portfolio ABEO Stock Details ABEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.57M	Buy	1,020,000 +500,000	+96%	+$2.5M	0.17%	103
2025 Q4	$2.74M	Hold	520,000	–	–	0.09%	126
2025 Q3	$2.75M	Hold	520,000	–	–	0.1%	128
2025 Q2	$2.95M	Hold	520,000	–	–	0.12%	115
2025 Q1	$2.48M	Hold	520,000	–	–	0.1%	107
2024 Q4	$2.9M	Hold	520,000	–	–	0.12%	101
2024 Q3	$3.29M	Hold	520,000	–	–	0.17%	89
2024 Q2	$2.2M	Hold	520,000	–	–	0.13%	88
2024 Q1	$3.77M	Hold	520,000	–	–	0.22%	75
2023 Q4	$2.61M	Buy	520,000 +468,000	+900%	+$2.06M	0.16%	83
2023 Q3	$219K	Buy	52,000 +32,000	+160%	+$121K	0.02%	120
2023 Q2	$80.6K	Buy	+20,000	New	+$70K	0.01%	117

Other funds holding ABEO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

CCC

Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nantahala Capital Management's ABEO Position: Q1 2026 in Review

Nantahala Capital Management increased its Abeona Therapeutics (ABEO) stake by 1% in Q1 2026, buying an estimated $250K and bringing the position to 5,013,052 shares worth $22.5M. The position accounts for 0.83% of the portfolio, ranked #33.

Nantahala Capital Management first reported a position in ABEO in Q4 2022 and has held it in 14 quarters since. The position peaked at $26.2M in Q4 2025. 108 funds tracked by Wall St. Rank hold ABEO as of Q1 2026.

Nantahala Capital Management held 5,013,052 shares of Abeona Therapeutics worth $22.5M as of Q1 2026.
Nantahala Capital Management bought 50,000 Abeona Therapeutics shares in Q1 2026, an estimated $250K.
Abeona Therapeutics made up 0.83% of Nantahala Capital Management's portfolio in Q1 2026, its #33 holding.
Nantahala Capital Management first reported a position in Abeona Therapeutics in Q4 2022 and has held it in 14 quarters since.
Nantahala Capital Management's Abeona Therapeutics position peaked at $26.2M in Q4 2025.
108 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2026.

Based on Nantahala Capital Management's 13F filing for Q1 2026, filed 15 May 2026.